Stryker Co. (NYSE:SYK) – Equities research analysts at Piper Jaffray Companies raised their Q4 2019 earnings per share estimates for Stryker in a research report issued on Thursday, July 25th. Piper Jaffray Companies analyst M. O’brien now anticipates that the medical technology company will earn $2.46 per share for the quarter, up from their prior forecast of $2.44. Piper Jaffray Companies currently has a “Overweight” rating and a $240.00 target price on the stock. Piper Jaffray Companies also issued estimates for Stryker’s Q4 2020 earnings at $2.72 EPS and FY2020 earnings at $9.02 EPS.
Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 25th. The medical technology company reported $1.98 EPS for the quarter, topping analysts’ consensus estimates of $1.93 by $0.05. Stryker had a return on equity of 25.98% and a net margin of 24.99%. The company had revenue of $3.65 billion for the quarter, compared to analysts’ expectations of $3.60 billion. During the same period in the prior year, the firm earned $1.76 earnings per share. The firm’s revenue was up 9.9% compared to the same quarter last year.
NYSE:SYK opened at $213.61 on Monday. The company has a quick ratio of 1.26, a current ratio of 2.07 and a debt-to-equity ratio of 0.67. The stock’s fifty day moving average price is $205.73. Stryker has a 52 week low of $144.75 and a 52 week high of $222.59. The firm has a market capitalization of $79.71 billion, a PE ratio of 29.22, a price-to-earnings-growth ratio of 2.58 and a beta of 0.87.
In related news, insider Timothy J. Scannell sold 4,666 shares of the stock in a transaction on Thursday, May 16th. The stock was sold at an average price of $186.71, for a total value of $871,188.86. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Glenn S. Boehnlein sold 2,700 shares of the stock in a transaction on Wednesday, May 8th. The shares were sold at an average price of $188.21, for a total value of $508,167.00. Following the completion of the transaction, the chief financial officer now directly owns 23,333 shares in the company, valued at approximately $4,391,503.93. The disclosure for this sale can be found here. Insiders have sold 18,698 shares of company stock worth $3,643,227 in the last ninety days. Corporate insiders own 7.20% of the company’s stock.
A number of large investors have recently bought and sold shares of SYK. D.B. Root & Company LLC grew its holdings in shares of Stryker by 3.0% during the second quarter. D.B. Root & Company LLC now owns 1,724 shares of the medical technology company’s stock worth $354,000 after purchasing an additional 50 shares during the last quarter. Welch Group LLC grew its holdings in shares of Stryker by 1.5% during the first quarter. Welch Group LLC now owns 3,774 shares of the medical technology company’s stock worth $745,000 after purchasing an additional 54 shares during the last quarter. Independence Bank of Kentucky grew its holdings in shares of Stryker by 4.9% during the first quarter. Independence Bank of Kentucky now owns 1,180 shares of the medical technology company’s stock worth $233,000 after purchasing an additional 55 shares during the last quarter. Benedict Financial Advisors Inc. grew its holdings in shares of Stryker by 1.1% during the first quarter. Benedict Financial Advisors Inc. now owns 5,235 shares of the medical technology company’s stock worth $1,034,000 after purchasing an additional 57 shares during the last quarter. Finally, Berman Capital Advisors LLC grew its holdings in shares of Stryker by 11.1% during the first quarter. Berman Capital Advisors LLC now owns 571 shares of the medical technology company’s stock worth $112,000 after purchasing an additional 57 shares during the last quarter. 73.53% of the stock is currently owned by hedge funds and other institutional investors.
Stryker Corporation operates as a medical technology company. The company operates through three segments: Orthopaedics, MedSurg, and Neurotechnology and Spine. The Orthopaedics segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. The MedSurg segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical devices for use in various medical specialties.
Further Reading: What is a balanced fund?
Receive News & Ratings for Stryker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker and related companies with MarketBeat.com's FREE daily email newsletter.